Company / EPS (Diluted)
Regeneron Pharmaceuticals EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$34.77
FY2025
5-year range
$18.46 / $71.97
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
#2 of 204
Health Care
What the data says
Among 204 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $2.98 in FY2016 to $71.97 in FY2023.
Based on SEC 10-K filings.
34.77 in FY2025 with a 5-year CAGR of +10.3%. Ranks 2nd among 204 companies in Health Care.
Declined from $71.97 to $34.77 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +4.4%
- 5-Year CAGR
- +10.3%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 204This company $34.77 Sector average -$0.89
▼
+3985.1% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 9.0% year-over-year.
- Ranks #2 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.77 | -9.0% |
| FY2024 | $38.22 | -46.9% |
| FY2023 | $71.97 | +135.8% |
| FY2022 | $30.52 | +65.3% |
| FY2021 | $18.46 | -13.3% |
| FY2020 | $21.29 | +105.9% |
| FY2019 | $10.34 | +34.3% |
| FY2018 | $7.70 | +39.5% |
| FY2017 | $5.52 | +85.2% |
| FY2016 | $2.98 | -19.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026